The role of stress in heart failure – ground for sex specific pathophysiology

M. Heffer¹, L. Zibar¹, B. Viljetic³, Z. Makarovic⁴

¹Department of Medical Biology, School of Medicine, Josip Juraj Strossmayer University of Osijek
4, Huttlerova St., Osijek, Croatia, 31000

²Department of Pathophysiology, School of Medicine, Josip Juraj Strossmayer University of Osijek
4, Huttlerova St., Osijek, Croatia, 31000

³Department of Chemistry, Biochemistry and Clinical Chemistry, School of Medicine, Josip Juraj Strossmayer University of Osijek
4, Huttlerova St., Osijek, Croatia, 31000

⁴Department of Cardiology, Clinical Hospital Osijek
4, Huttlerova St., Osijek, Croatia, 31000

mheffer@mefos.hr

In the last hundred years modern society went through numerous changes in life style, dietary habits, work load, physical activity and other environmental factors. As a species we are not well adapted to new demands. Higher levels of stress hormones provoke various effects, especially gradual change in the sensitivity of adrenergic, glucocorticoid and insulin receptors. All these changes are mutually associated and they gradually lead to metabolic syndrome, obesity, diabetes, heart failure and other types of pathology depending on genetic makeup and environmental factors. The aim of this paper is to summarize current knowledge concerning the impact of stress on cardiac function. Whereas stress response is sex specific we would emphasize a potential difference in pathophysiology of ischemic heart failure in men and women.

Modern medicine has misinterpreted autonomous nervous system functions for years and this was reflected in heart failure (HF) and arterial hypertension therapy. Stress before the onset of menopause has a lesser effect on cardiac function compared to stress after menopause. Postmenopausal women have a significantly higher risk of heart disease, which is related to the diminished protection of the female hormonal cycle, but low doses of estrogen have not proven protective in postmenopausal women. Potential new targets of sex-specific cardiac therapy would come from better understanding of the molecular mechanisms exerted by nuclear receptors for steroid hormones, transcription factors involved in heart remodeling, cross-talk in adrenergic signaling pathways and their down-stream molecules.

Keywords: heart failure, stress, adrenergic receptors, sex specific.

Introduction. America’s top 15 most prescribed drugs by dispensed prescriptions published on the internet pages (www.forbes.com/2010/05/11/; source – IMS National Prescription Audit) belong to the top six categories: pain killers, blood pressure and cholesterol lowering drugs, medication of hypothyroidism, anxiety/depression and type two diabetes. Six out of top 15 are blood pressure lowering medications. A huge market of 83 million dollars in the year 2010 belongs to the second most prescribed medication – simvastatin – a drug efficient in cholesterol lowering. If Dr. Hans Selye, the scientist who established stress reaction, would be asked to interpret such data, he would recognize population based symptoms of the most common modern disease – chronic stress. Number of scientific publications on this subject doubles every few years, but it seems like we still do not have a handle on the large scale health risks caused by the new pande-
Trained as medical doctors, we often look after patients as removed from their social environment and make conclusions based on the currently presented isolated set of symptoms. In this paper we try to bring together pieces of knowledge connecting autonomous nervous regulation of the heart’s function, major signaling pathways executing molecular instructions in stress response and the role of stress in the development of heart failure. Special notice should be taken of sex-specific molecular mechanisms, suggesting a difference in pathophysiology.

**The anatomy of cardiac innervations.** Two branches of the autonomous nervous system, parasympathetic and sympathetic, fight for the same targets, opposing and/or modulating each other. Each branch consists of efferent and afferent fibers. The efferent parasympathetic innervations of heart (Fig. 1) originate in medullar nuclei (nucleus ambiguous, nucleus tractus solitarius and dorsal motor nucleus), whose axons follow vagal nerve to intrinsic ganglia located on epicardial surface of atria [1]. Postganglionic fibers of intrinsic ganglia cross AV groove, penetrate myocardium and terminate in subendocardium (more atrial then ventricular) modulating SA and AV nodal function [2]. Acetylcholine, exclusive neurotransmitter of the efferent parasympathetic branch, operates through nicotinic receptor on postganglionic neurons and muscarinic receptors expressed on cardiomyocytes [3]. The density of muscarinic receptors is much higher in the atria compared to the ventricles [4], this is reflected in a lesser effect on the contractility than on the heart rate. Along predominant subtype M2, receptors M1 and M3 are up-regulated in the heart failure (HF) [5]. Muscarinic receptors on cardiomyocytes and conductive system are Gi protein-coupled, causing decrease in cellular cAMP and decreasing contractile forces and velocity [3].

More prolific efferent cardiac sympathetic innervations originate from the intermediolateral cell column of the spinal cord (commonly from T1 till T5), follow spinal nerves until superior, middle and stellate cervical ganglion as well as upper thoracic ganglia [2]. The postganglionic fibers arising from sympathetic trunk follow the coronary arteries and penetrate myocardium. Neurotransmitter of the sympathetic branch is norepinephrine, but cotransmission of epinephrine is well documented in panic disorder [6] and essential hypertension [7], in which case catecholamine level released by sympathetic nerves is increased for 10 %. Another neurotransmitter, neuropeptide Y (NPY) is readily found in sympathetic nerve of gut and liver [8] of healthy individuals, but also is acutely released during maximal aerobic exercise at high rates of cardiac nerve firing and chronically released in patients with HF [9]. Catecholamine work through two major classes of adrenergic receptors (AR), α (α1, α2) and β (β1, β2, β3), members of the super family of G protein-coupled receptors (Fig. 2). Different subtypes of α-ARs regulate cardiac contractility and peripheral resistance; α1a, - and α1d-constitute the majority of cardiac α-ARs [10], α1d – is predominant AR of human coronary arteries [11], while three subtypes of α2-AR (α2A, α2B and α2C) mediate vasodilatation of arteries, vasoconstriction of veins, platelet aggregation and various endocrine responses to the sympathetic stimulation [12]. Taking a
The cardiac response to catecholamine stimulation in healthy mammalian heart is predominantly mediated by β-AR as follows; 70–80 % by β1, 20–30 % by β2, and β3 account just minimal contribution [4, 13]. Using the functional criteria, sensitivity toward typical β1-AR agonist CGP-12177 in β1-knockout mice [14, 15], as well as molecular cloning techniques [16] it has been established that β1-AR exist in multiple active con formations functionally opposing each other. All adrenergic receptors respond to both, norepinephrine and epinephrine, but they are not equally sensitive to these stimuli and the final outcome of the ligand binding depends on the intracellular signaling pathway. Increased force of contraction, accelerated relaxation and increased beating rate are outcome of the activation of Gs protein by β1- and β2-AR, followed by activation of adenylate cyclase, production of cAMP and activation of protein kinase A (PKA) [17]. PKA mediates short-term inotropic effect by phosphorylation of few Ca2+ channels or pumps (sarcolemmal L-type Ca2+ channels, phospholamban – sarcoplasmatic Ca2+ pump and sarcoplasmatic SR Ca2+ release channels) and proteins reducing myofilament Ca2+ affinity (troponin I and myosin binding protein C). Prolonged activation of this signa-
finding sympathetic efferent neurons in intramural places [1]. Armour suggested three levels of cardiac autonomous regulation; the simplest one, intrinsic and working on short range-bit to bit; the second one on the level of cardiac plexus and nodose ganglion, working on middle range-minutes or hours; the tertiary level located in the medulla oblongata and cortical centers providing long lasting changes (days, months or even years).

Cardiac innervations are still not fully understood and further studies need to deal with effects of over-stimulation, sex-specific aging and potential of regeneration.

### Sympathetic excitation in the development of cardiovascular pathology

HF is associated with decreased inotropic response. At first glance, pharmacological treatment at the level of $\alpha_1$ and $\beta_1$-AR should lead to an improvement. Non-selective agonists, including epinephrine and norepinephrine, have adverse effects like hypertension and arrhythmia [30] due to $\alpha$-AR stimulation. The development of more selective agonist for $\beta_1$-AR was the next logical step. Dopamine infusion at intermediate doses stimulates predominantly cardiac $\beta_1$-AR, while lower doses work just on dopamine receptors in splanchic and renal arterial bed [31]. Dopamine was neglected as a possible compound for long term treatment because of the respiratory depressant effect [32] and overall unpredictable outcomes in HF [33]. Neither one of the next generation, more selective $\beta_1$-AR agonist (prenalterol, xamoterol, dobutamine), was more successful [34–36]. Creation of a highly selective agonist was the ultimate goal till the end of the nineties. Some tried to overcome receptor specificity barriers by designing inhibitors of down-stream signaling molecules. Milrinone and enoximone are selective inhibitors of cAMP-specific phosphodiesterase (PDE) III isoenzyme in myocardium and smooth muscle, prolonging the half life of cAMP and increasing intracellular Ca$^{2+}$, both without benefit over placebo [37, 38] in long term treatment of ischemic heart failure. Milrinone was found to be beneficial in treatment of dilated cardiomyopathies, treatment of low output syndrome following cardiac surgery and patients with congestive HF prior to cardiac surgery due to a combination of anti-apoptotic and positive inotropic effects [39].

The large, randomized, double blind placebo-controlled clinical trials were over and over pointing to either the goal of finding selective agonist was tricky to achieve or the concept of sympathomimetic boost to failing heart was wrong. The paradigm of the failing heart craving more sympathetic stimulation was fed by findings of both anatomical and functional cardiac sympathetic denervation. Chidsey and Braunwald performed studies on excised atrial tissue obtained during heart surgery [40] and found a significant reduction of norepinephrine concentration in the failing heart. Alman and coworkers interpreted positron emission tomography with carbon-11-hydroxyephedrine (radioisotope taken up by sympathetic nerves) after acute myocardial infarction as patchy denervation [41]. Also, progression of HF is accompanied with $\beta_1$-AR selective down regulation [42, 43]. Approximate ratio of 50:50 $\beta_1/\beta_2$-AR is not just shifted in favor of $\beta_2$-AR, yet both receptors become uncoupled of their down-stream signaling pathways and desensitized to adrenergic stimu-
lation [44–46]. All of this data justified the use of β-AR agonist, but clinical results were showing the opposite.

One of the crucial pieces in the puzzle came from Cohn and coworkers’ study [47] in which they measured plasma norepinephrine at supine rest and found high correlation between concentration of norepinephrine in venous blood and risk of mortality. The concentrations of resting norepinephrine in their study remain stable on successive days, and were a sign of general sympathetic-nervous-system activation, while epinephrine was a marker of acute stress response [48] and variable from day to day. Similar data were coming out of succeeding studies [49, 50] proving that in untreated patients with congestive heart disease cardiac norepinephrine spillover was increased as much as 50-fold, that corresponded to the levels in healthy adult during near maximal exertion. Increased cardiac adrenergic drive preceded generalized sympathetic activation [51] and manifested as 4–5 times higher than normal norepinephrine spillover in the mild HF, as well as in a heart with a predisposition for ventricular tachycardia and ventricular fibrillation [52]. Along with norepinephrine the spillover of NPY [8], neuropeptide which is not subjected to neuronal reuptake and have been shown to cause coronary vasoconstriction, inhibiting vagal activity and triggering ventricular arrhythmias through Y(2) receptors [53], also increases. Beside peripheral drive, in the rat coronary ligation model, norepinephrine is also increased in the central nervous system in the locus coeruleus and nucleus in which its project – paraventricular nucleus of the hypothalamus – the one which participates in the regulation of autonomous nervous system [54, 55].

In the meantime, transgenic mice with overexpression of β₁-AR and β₂-AR were generated [56]. Initial observations, performed on young animals, show no cardiac pathology with up to 60-fold overexpression of β₂-AR [57] – the promising target for restoration in heart failure. Longer observation, however, reveals quite a different picture; both transgenic models, overexpressing β₁-AR [58] or β₂-AR [59] develop cardiomyopathy and heart failure. The same result was obtained with mice overexpressing down-stream signaling molecule for both adrenergic receptors; cardiac stimulatory G protein alpha subunit-Gsα [60, 61] and alpha catalytic subunit (Caα) of PKA [62].

All these studies concluded that selective down regulation of β-AR in patients with HF is a compensatory and protective mechanism, shifting paradigm from sympathetic stimulation toward blocking. In the beginning, β-blockers were introduced as a therapy to control the tachycardia associated with HF which unexpectedly reduced mortality in acute myocardial infarction [63]. Although few trials were conducted in following years, the first large randomized clinical trial showed clear evidence of mortality benefit was released in 1999 [64, 65]. Currently three types of β-blockers classified as β₁-AR selective, non-selective β-AR blockers and non-selective βα-AR blockers are in use. Interestingly, non-selective βα-AR blockers like carvedilol result in vasodilatation secondary to α-AR blockade lowering aortic pressure and are proving to be superior over more selective blockers [66].

Nowadays we have overall acceptance of HF development is connected with progressive remodeling of cardiac sympathetic response. Although we know how to alleviate consequences of this response, we still do not know enough about the trigger of changes, early signs, risk factors, sex specific dynamic and therapy.

The adrenergic receptors behavior under acute and chronic stress. In 1936 Dr. Hans Selye presented his finding of General Adaptation Syndrome explaining how various nocuous agents (exposure to cold, surgical injury, excessive muscular exercise, sublethal intoxication) produced the same typical response in experimental animals [67]. He described three stages of the syndrome development: the initial one expressed as a general alarm (decrease in size of lymphoid organs and fat tissue, fall of body temperature, formation of erosions in digestive tract), the phase of building up resistance and the phase of exhaustion after a period of a prolonged stress. The article was a cornerstone in the field of neuropsychiatry, kicking up an avalanche of studies and helping to reveal the effect of hormones and stress on the brain function. Today we understand stress as a multi-system response to challenges threatening homeostasis, having bearable or overwhelming allostatic load and potential health consequences [68].

All of the situations like the first jump with parachute (as well as consequent jumps), running in front of an enraged bull, waiting for a big exam, being threaten with a gun, have in common the surge of epinephrine
and co-released cortisol from adrenal gland into the bloodstream. These two hormones activate responses in multiple organs having adrenergic or cortisol receptors, particularly response of the stress axis, the hypothalamic-pituitary-adrenal (HPA) axis, and sympathetic-adrenal medullary system. The mark of HPA activation is elevation of corticotropin releasing factor (CRF), synthesized by a discrete population of neurons in parvocellular part of the paraventricular nucleus in the hypothalamus and released into hypophysial-portal circulation [69]. Neuropeptide arginine vasopressin (AVP) is co-released at the same nerve endings. CRF stimulates synthesis and release of adenocorticotropic hormone (ACTH) from the anterior lobe of the pituitary gland while binding of arginine vasopressin to V1b pituitary receptors enhance release of ACTH in the system circulation [70]. ACTH induces glucocorticoid production and its release from the adrenal cortex. Besides numerous physiological and metabolic effects (suppression of immune, reproductive and digestive organs, inhibition of growth, glycolysis, proteolysis and lipolysis), glucocorticoids are one of the six known transcriptional activators of epinephrine synthesizing enzyme phenylethanolamine N-methyltransferase (PNMT) [71–73]. This enzyme is confined in its distribution just to the adrenal medulla and adrenalin synthesizing neurons of the brain stem in healthy individuals, consequently producing more epinephrine. At the same time, a parallel track is also being activated; the sympathetic system releases norepinephrine stimulating target organs having adrenergic receptors, including adrenal medulla. Epinephrine regulates its own production by inhibiting PNMT [74]. It is one of many inhibitory loops throughout HPA axis, bringing all players back to basal level.

In between various animal models of stress (foot shock, electric shocks, forced swimming, forced running, etc.) immobilization on wooden board is considered a putative model of posttraumatic stress disorders (PTSD). Single and repeated exposures induce dysregulation of the resting activity of the HPA axis [75], observed as increase in resting corticosterone levels [76, 77]. Dysregulation of HPA triggers multiple changes in target organs. The transcriptome in the adrenal medulla after acute and chronic stress exposure is very different; the number of transcripts significantly differed in the rat medulla after single immobilization — it was bigger (651 up and 487 down) than after immobilization on six consecutive days (370 up and 195 down) [78]. Transcription factors and cell signaling molecules go through the largest changes accompanied with transcripts related to growth factors, apoptosis, neurosecretion, heat shock proteins, structural proteins, chemokines, cytokines, metabolism and proteases.

Immediate cardiovascular response to raised levels of epinephrine at the beginning of the stress response is increased blood pressure and heart rate, respectively. The heart is very sensitive to the changes of adrenergic levels, because 95% of norepinephrine released on the sympathetic nerves is being recaptured [79]. In stress response, levels of epinephrine are major drive of cardiac performance. Hence, changes in norepinephrine reuptake mechanism and/or neurotransmitter load would sensitize the heart to arrhythmia development during intense sympathetic activation, as during panic attacks, for example [6].

In a model of foot shock stress Basani reported supersensitivity of isolated rat heart pacemaker to β2-selective agonists [80] suggesting increased β2-signaling. At the same time right atria were subsensitive to selective β1-agonist. Observed remodeling of adrenergic receptors was canceled by treatment with the mifepristone, glucocorticoid receptor antagonist, indicating involvement of glucocorticoid mediated mechanism [81]. Similar experiments repeated on female rats demonstrated more elevated plasma corticosterone in female versus male animals, independent of estrus cycle, the same changes of adrenergic receptors during diestrus and lack of changes in estrus [82]. This data suggests a role of sex steroids at least in remodeling of female heart. Changes in adrenergic receptors also take place in adipose tissue manifested as decreased expression of the β2- and β3-AR accompanied with increased expression of β1-AR [83] and reflected in altered sensitivity to insulin [84]. While increase of β1-signaling during stress response could be interpreted as protective because it was directing heart from activation of PKA, Ca2+ overload and apoptosis caused by β2-AR, on the other hand, raises insulin resistance in fat tissue, which is a bad strategy on the long term, leading to a «thrifty metabolism». However, recently used fluorescence resonance energy transfer (FRET) microscopy demonst-
rated particularity in distribution of adrenergic receptors in cardiomyocytes of failing heart [85]. Besides being more expressed, \( \beta_2 \)-AR in failing heart are redistributed from their common place at transverse tubules to the cell crest – compartment of cAMP production reserved for \( \beta_1 \)-AR. Final outcome is \( \beta_1 \)-AR coupled to different signaling mechanism and behaving like \( \beta_2 \)-AR, also proved in the development of cardiomyopathies in \( \beta_2 \)-AR transgenic animals \([59, 86]\). To make stress response of the heart even more complicated, different heart regions express different shift in adrenergic receptors; murine right ventricles express decreased level of \( \beta_1 \)-AR [87].

The adrenergic receptor remodeling is accompanied by the changes in the level of catecholamine. Elevated urinary concentrations of norepinephrine and epinephrine are observed in patients with posttraumatic stress disorder (PTSD) \([88, 89]\). Stress elevates the expression of PNMT mRNA \([90]\) in a glucocorticoid dependent manner, especially after repeated immobilization stress, but not only at the adrenal medulla and neurons of the brain steam, but also at sympathetic nerve endings and cardiac tissue \([91, 92]\). Epinephrine is increased after the first immobilization, while levels of norepinephrine rise after the seventh immobilization \([87]\). Epinephrine is also found in the samples of blood from coronary sinus, released by the sympathetic nerves of heart in patients with essential hypertension \([7]\)

The heart rhythm transcriptome genes encoding adrenergic receptors, connexins, cadherins, plakophilins, ankyrins, ion channels and transporters have significant heart chamber sex differences observed in the rat animal model \([101]\). Differences become particularly prominent in knockout models challenged by physiological ligand, agonist and antagonist of various receptors participating in stress response \([102]\).

Environmental and sex-specific genetic factors are reflected on the pathology: prevalence of hypertension in Western society is higher in men aged 30–45 years than in women of similar age. On the other hand prevalence of hypertension in women after this age increases to levels similar to or exceeds those in men \([103–105]\). Reverse man versus women epidemiology is observed in vasoconstrictor disorders like Raynaud’s disease, postu-

Right now we do not have any reliable and easy to follow stress-specific marker which could be used in studies of human or animal exposure to different stressors and their different intensity. Animal studies are pointing to significant remodeling of adrenergic receptors in heart and blood vessels in chronic stress, but even in animal models we do not know how to prevent them. Also, most animal studies are short-term, observing changes provoked after consecutive stress exposure, while observations from human studies predict more then a decade or two long progression of cardiac pathology. We are looking not just for an animal model, but also for a study plan which would combine the major risk factors and follow up data on vital functions in a long term study.
ral orthostatic tachycardia syndrome and vasomotor symptoms (hot flashes) of menopause and migraine \[106\]. In both human and animal heart pathology differences is connected with estrogen levels \[107–109\].

Because women develop manifestation of coronary disease 10 years later then men, on average, and present with myocardial infarction 20 years later \[110\], general preconception is still how cardiovascular disease (CVD) is not a leading cause of mortality in women. The consequences of this misconception are numerous: the two-thirds of women, who died suddenly, had unrecognized CVD symptoms, 35 % of heart attacks in women are believed to go unnoticed or unreported, women present later and are more sick at the time of diagnosis, they are less likely to undergo interventional cardiology, undergo cardiac rehabilitation and return to work after the first heart attack – which they are less likely to live through \[111\]. Women with acute coronary disease are more likely to present atypical symptoms: vomiting, abnormal pain location, nausea, dizziness and fatigue. The pathophysiology of HF is also different in men and women: men more frequently develop diastolic HF with preserved left ventricular function and normal ejection fraction accompanied with prolonged history of arterial hypertension and comorbidities \[112, 113\], men more frequently have systolic HF because of coronary artery disease \[114\]. Pressure overload, arterial hypertension, diabetes and aging itself initiate myocardial hypertrophy. The hypertrophy generates alterations in cardiac geometry, referred as ventricular remodeling, measured by transthoracic echocardiography (two-dimensional or three-dimensional) and expressed as left ventricular (LV) volume, mass, sphericity index or LV mass/volume. The first stage of hypertrophy is adaptive response to stress due to increase of cardiomyocytes size and deposition of extracellular matrix \[115\]. Further progression of hypertrophy becomes maladaptive if accompanied with fibrosis (involving collagen deposition) and apoptosis. Male hearts develop more easily pathological hypertrophy, while female ventricular remodeling follows the pattern of diastolic HF having a greater risk of adverse outcome as baseline ejection fraction is decreasing \[113, 116\].

Chronic hypertension induced ventricular hypertrophy, left ventricular fibrosis and action potential prolongation is observed in animal models of both aging male and female Spontaneously Hypertensive Rats (SHR) \[117\]. Male animals from 15 months of age develop left ventricular thinning, systolic and diastolic dysfunction, which is not present in females at the same age. In the mouse model of pressure overload by transverse aortic constriction, males show more hypertrophy than females and females develop concentric while males develop eccentric hypertrophy \[118\]. Induction of matrix-related genes and a repression of mitochondrial genes in maladaptive stress response are attenuated in estrogen receptor β knockout mice pointing to molecular mechanism of estrogen protection. Estrogen therapy in male Gαq transgenic mice prevent HF by inhibition of apoptosis-regulated signaling kinase-1 \[119\].

Women and men respond differently to chronic HF therapies, tailored to better fit to male than female pathology \[120\]. Women benefit more from angiotensin receptor blockers, while men benefit more from angiotensin converting enzyme inhibitor \[121\]. Low dose of estrogen attenuate structural and functional remodeling in an animal model of HF \[122\]. Contrarily, estrogen treated female rats have a greater postmyocardial infarction survival \[123\].

Also, estrogen did not improve ischemia and endothelial function in randomized controlled trials in postmenopausal women \[124\]. In survival studies, women had advantage in advance HF if presented with nonischemic etiology \[120\].

The role of stress in CVD development is not fully investigated. Sexual dimorphism in the stress response, especially its relation to female hormonal cycle, has been observed in animal models and in humans \[125, 126\]. Stress induces different changes of adrenergic receptors and their signaling pathways. While all subtypes of α1-AR decrease in female mice, it happens just to α1A-AR in a CRH gene knockout, suggesting the role of CRH in down-regulation of others. However, β1-AR decreases in male mice, but remains stable in female mice. Also, while the ability of α1-AR agonist to inhibit insulin secretion was attenuated in male insulin receptor substrate 2 knockout animals, female animal developed mild obesity and progressed less rapidly to diabetes under adrenergic stimulation \[127\]. Adrenergic receptors and their down-stream signaling molecules exert a variety of effects and these molecules are good
candidate genes in gene polymorphism studies dealing with sex-specific pathology. The polymorphism in the nuclear receptor genes, like glucocorticoid receptor, was documented as a significant sex specific factor in rising stress response to psychosocial stimuli [128]. Also, the sex specific pathway of cardioprotection mediated by estrogen receptors include transcription factor myocyte enhancer factor 2 and class II histone deacetylases, potential targets in sex specific therapy [129]. Polymorphism in the \( \beta_1 \)-AR and \( \beta_2 \)-AR increases cardiovascular risk in women, more to microvascular pathology than to obstructive coronary disease [130].

Difference in stress-response reactions is noticed in the peripheral and central nervous systems. Functional brain imaging studies of central stress response circuitry (amygdale, hypothalamus, hippocampus, brainstem, orbitofrontal cortex, medial prefrontal cortex and anterior cingulated gyrus) found the most prominent differences between men and women during early follicular phase [126]. Activation of central stress response circuitry somehow predisposed women for development of more adverse effects; about twice as many women as men would develop PTSD, under the same exposure to trauma [131].

Also symptoms of further exacerbation are different, while anxiety is better predictor of PTSD in men, depression is found in women [132]. Psychosocial variables were recently associated with morbidity and mortality in CVD patients [133]. Psychosocial stress and depression might have role in accelerated aging [134]. Telomere length is a marker of biological aging and presence of stressor. A telomerase deficient mouse model is recently used in HF studies [135]. Emotional/cognitive symptom cluster composed of worrying, feeling depressed and expressing cognitive problems predicts a high risk for a cardiac event [136]. Insomnia is a risk factor and symptom of stress, depression and anxiety [137], highly prevalent in patients with chronic heart disease [138].

Besides all indirect links between stress and cardiac disease in humans, Tako-Tsubo syndrome, firstly described by Sato et al in 1990 (Japan), directly links excessive sympathetic stimulation triggered by intense psychological or physical stress and acute cardiomyopathy in the absence of arterosclerotic coronary artery disease [139, 140].

Stress is a multi organ disease. The heart is just one organ affected after years, even decades of increased sympathetic activity. Additional risk factors, genetic, metabolic, socioeconomic and environmental bring a different load on homeostatic mechanisms. The development of HF differs between male and female, this is visible in the stress induced heart remodeling. Close observation of the differences will bring us closer to sex-specific therapy in the near future.

M. Хеффер, Л. Забар, Б. Вильємич, З. Макарович

Роль стресу у серцевій патології – основа міжставевих патофізіологічних розбіжностей

Резюме
За останнє століття сучасне суспільства зазнавало багаточисельних змін у способі життя (відпочинок, харчування, навантаження, фізичні активності), а також під впливом часів докілля. Як біологічний вид ми не дуже добре адаптувалися до нових умов. Вищий рівень гормонів стресу спричиначує різні ефекти, поступово змінюється чутливість адаптергічних, глюко- кортикокоїдних і інсулінових рецепторів. Усі ці зміни взаємовідносин і генетичних і екологічних факторів приводять до таких метаболічних синдромів, як ожиріння, цукровий діабет, серцева недостатність тощо. Оскільки відповідь на стрес зазначають і від стану, потрібно враховувати можливу різницю у патофізіології серцевої недостатності у чоловіків і жінок. Протягом багатьох років функції вегетативної нервової системи небезпечно трактувалися сучасною медициною, що відбилося на терапії серцевої недостатності і гіпертензії. Вплив стресу на серцеву функцію у період до і після менопаузи різняться. У жінок у постменопаузі значно підвищується ризик серцево-судинних захворювань, який визначається із змінами в функції жіночого гормонального циклу. Гібність виділення молекулярних механізмів від ядерних рецепторів середовищ гормонів, факторів транскрипції, які бере участь у ремоделюванні серця, перекресних адаптергічних і синальних шляхів та їхніх ефекторних молекул призвела до постановки нових задач для гендер-спеціфічної терапії.

Ключові слова: серцева недостатність, стрес, адаптергічні рецептори, статева специфічність

M. Хеффер, Л. Забар, Б. Вильємич, З. Макарович

Роль стресу в серцевій патології – основа патофізіологічних різниць між полами

Резюме
За останнє століття стараніще соціального контексту претерпіло значні зміни в образі життя (приміхання, спосіб питання, наслідки фізичного активності), а також під впливом факторів окружаючої средою. Коли біологічний вид ми не дуже добре адаптувалися до нових умов. Більше змін у гормональному стресу приводять до різних ефектів, поступово змінюється чутливість адаптергічних, глюко- кортикокоїдних і інсулінових рецепторів. Усі ці зміни взаємовідносин і генетичних і екологічних факторів приводять до таких метаболічних синдромів, як ожиріння, цукровий діабет, серцева недостатність тощо. Оскільки відповідь на стрес зазначають і від стану, потрібно враховувати можливу різницю у патофізіології серцевої недостатності у чоловіків і жінок. Протягом багатьох років функції вегетативної нервової системи небезпечно трактувалися сучасною медициною, що відбилося на терапії серцевої недостатності і гіпертензії. Вплив стресу на серцеву функцію у період до і після менопаузи різняться. У жінок у постменопаузі значно підвищується ризик серцево-судинних захворювань, який визначається із змінами в функції жіночого гормонального циклу. Гібність виділення молекулярних механізмів від ядерних рецепторів середовищ гормонів, факторів транскрипції, які бере участь у ремоделюванні серця, перекресних адаптергічних і синальних шляхів та їхніх ефекторних молекул призвела до постановки нових задач для гендер-спеціфічної терапії.
ческим синдромом, как ожирение, сахарный диабет, сердечная недостаточность и др. Поскольку ответ на стресс зависит и от пола, нужно учитывать возможную разницу в натофизиологии сердечной недостаточности у мужчин и женщин. В течение многих лет функции вегетативной нервной системы неоднократно подвергались современной медициной, что отразилось на теории сердечной недостаточности и гипертрофии. Влияние стресса на сердечную функцию в период ее межмозгового равновесия. У женщин в постменопаузе значительно повышается риск сердечно-сосудистых заболеваний, определяемый снижением защитной функции женского гормонального цикла. Более углубленное изучение молекулярных механизмов действия идентификации рецепторов стероидных гормонов, факторов транскрипции, участвующих в ремоделировании сердца, перекрестных адаптерных сигнальных путей и их эффекторных молекул приведет к постановке новых задач для генеративной биологии.

Ключевые слова: сердечная недостаточность, стресс, адренергические рецепторы, половая специфичность.

REFERENCES


64. Segev A., Mekori Y. A. The cardiac insufficiency bisoprolol study II // Lancet.–1999.–353, N 9161.–P. 1361.


88. Southwick S. M., Brenner J. D., Rasmusson A., Morgan C. A., 3rd, Arnsten A., Charney D. S. Role of norepinephrine in the pa-
96. Saavedra J. M., Benicjky J. Brain and peripheral angiotensin II play a major role in stress // Stress.–2007.–10, N 2.–P. 185–193.


UCD 616.1 + 612.176
Received 10.01.11